Submitted for Publication: January 31, 2014; final revision received July 17, 2014; accepted July 21, 2014.
Published Online: November 19, 2014. doi:10.1001/jamapsychiatry.2014.1741.
Study concept and design: Kircher, Wittchen, Konrad, Ströhle, Reif, Arolt, Lueken.
Acquisition, analysis, or interpretation of data: Hahn, Straube, Wittchen, Konrad, Ströhle, Wittmann, Pfleiderer, Arolt, Lueken.
Drafting of the manuscript: Hahn, Kircher, Arolt, Lueken.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Hahn, Wittchen, Lueken.
Obtained funding: Kircher, Wittchen, Konrad, Ströhle, Arolt.
Administrative, technical, or material support: Hahn, Kircher, Straube, Wittchen, Konrad, Ströhle, Wittmann, Reif, Arolt.
Study supervision: Kircher, Straube, Wittchen, Konrad, Ströhle, Pfleiderer, Lueken.
Conflict of Interest Disclosures: Dr Kircher received fees for educational programs from Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Lundbeck, Pfizer, and Servier; received travel support/sponsorship for congresses from Servier; received speaker honoraria from Janssen-Cilag; and received research grants from Lundbeck and Pfizer. Dr Wittchen has served as a general consultant (not related to the product) for Essex Pharma, Organon, Pfizer, and Servier and has received grant funding for his institution from Essex Pharma, Lundbeck, Novartis, Pfizer, sanofi-aventis, Servier, and Whyet. Dr Konrad received fees for an educational program from Esparma GmbH/Aristo Pharma GmbH, Lilly Deutschland GmbH, MagVenture GmbH, and Servier Deutschland GmbH. Dr Ströhle received research funding from the European Commission (FP6), the German Federal Ministry of Education and Research, and Lundbeck and speaker honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Lundbeck, Pfizer, UCB, and Wyeth. Dr Reif participated in 2 noninterventional trials sponsored by AstraZeneca. Dr Arolt is member of advisory boards and/or gave presentations for AstraZeneca, Eli Lilly and Company, Janssen-Organon, Lundbeck, Pfizer, Servier, and Wyeth and received research grants from AstraZeneca, Lundbeck, and Servier. Dr Ströhle has received educational grants given by the Stifterverband für die Deutsche Wissenschaft, the Berlin Brandenburgische Akademie der Wissenschaften, the Boehringer Ingelheim Fonds, and the Eli Lilly International Foundation. No other disclosures were reported.
Funding/Support: This work is part of the German multicenter trial Mechanism of Action in CBT (MAC), which is supported by projects 01GV0615 and 01GV0611 (neuroimaging study) by the German Federal Ministry of Education and Research (BMBF) as part of the BMBF Psychotherapy Research Funding Initiative.
Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Previous Presentation: This paper was presented as a poster at the 20th Annual Meeting of the Organization for Human Brain Mapping; June 9, 2014; Hamburg, Germany. The paper was presented at the 27th European Colleague in Neuropsychopharmacology Congress; October 19, 2014; Berlin, Germany.
Additional Information: The following principal investigators (PIs) participated in the MAC trial (areas of responsibility): V. Arolt (overall MAC program coordination), Münster, Germany; H.-U. Wittchen (PI for the randomized clinical trial [RCT] and manual 4 development), Dresden, Germany; A. Hamm (PI for psychophysiology), Greifswald, Germany; A. L. Gerlach (PI for psychophysiology and panic subtypes), Münster; A. Ströhle (PI for experimental pharmacology), Berlin, Germany; T. Kircher (PI for functional neuroimaging), Marburg, Germany; and J. Deckert (PI for genetics), Würzburg, Germany. Additional site directors in the RCT component of the program are G. W. Alpers, Würzburg; T. Fydrich and L. Fehm, Berlin-Adlershof, Germany; and T. Lang, Bremen, Germany. The following staff members participated by site: C. Melzig, J. Richter, S. Richter, and M. von Rad, Greifswald (coordinating site for psychophysiology); H. Bruhn, A. Siegmund, M. Stoy, and A. Wittmann, Berlin-Charité, Germany (coordinating center for experimental pharmacology); I. Schulz, Berlin-Adlershof; A. Behnken, K. Domschke, A. Ewert, C. Konrad, B. Pfleiderer, C. Uhlmann, and P. Zwanzger, Münster (overall MAC program coordination, genetics and functional neuroimaging); J. Eidecker, S. Koller, F. Rist, and A. Vossbeck-Elsebusch, Münster (coordinating site for psychophysiology and subtyping); B. Drüke, S. Eskens, T. Forkmann, S. Gauggel, S. Gruber, A. Jansen, T. Kellermann, I. Reinhardt, and N. Vercamer-Fabri, Marburg/Aachen, Germany (coordinating center for functional neuroimaging); F. Einsle, C. Froehlich, A. T. Gloster, C. Hauke, S. Heinze, M. Hoefler, U. Lueken, P. Neudeck, S. Preiß, and D. Westphal, Dresden (coordinating site for data collection, analysis, and the RCT); A. Reif and C. Gagel, Würzburg Psychiatry Department (coordinating center for genetics); J. Duerner, H. Eisenbarth, A. B. M. Gerdes, H. Krebs, P. Pauli, S. Schad, and N. Steinhäuser, Würzburg Psychology Department; V. Bamann, S. Helbig-Lang, A. Kordt, P. Ley, F. Petermann, and E.-M. Schroeder, Bremen. Additional support was provided by X. Graehlert and M. Käppler, KKS Dresden (coordinating center for clinical studies).